Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT05108870

TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers

A Randomized Phase I/II Trial of TheraT® Vectors Expressing HPV16 Specific Antigens in Combination With Neoadjuvant Chemotherapy Followed by Transoral Robotic Surgery or Risk/Response Stratified Chemoradiotherapy for Locoregional HPV16+ Oropharyngeal Cancer

Status
Not Yet Recruiting
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
98 (estimated)
Sponsor
University of Chicago · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Doctors leading this study hope to learn about the safety and effectiveness of combining medications HB-201 and HB-202 (also known as TheraT® vectors) with chemotherapy using carboplatin and paclitaxel in the beginning of the study (induction) and if combining these medications can increase tumor shrinkage after therapy and reduce the amount of radiotherapy and chemotherapy that will later be needed. In addition, the study is looking at ways to reduce side effects overall using robotic surgery, chemotherapy and radiotherapy, or radiotherapy alone. Your participation in this research will last about 2 years. HB-201 and HB-202 are experimental (meaning the US Food and Drug Administration (FDA) has not approved these drugs), and therefore they can only be given in a research study.

Conditions

Interventions

TypeNameDescription
DRUGHB-201A anti-cancer vaccine that treats HPV-related cancers.
DRUGHB-202A anti-cancer vaccine that treats HPV-related cancers.
DRUGCarboplatinChemotherapy drug.
DRUGPaclitaxelChemotherapy drug.
PROCEDURETransoral Robotic SurgeryTransoral robotic surgery is a procedure to remove mouth and throat cancers in which a surgeon uses a sophisticated, computer-enhanced system to guide the surgical tools.

Timeline

Start date
2026-07-17
Primary completion
2027-01-01
Completion
2027-01-01
First posted
2021-11-05
Last updated
2026-03-25

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT05108870. Inclusion in this directory is not an endorsement.